|
|
|
| Clinical effect and safety of BiPAP combined with pulmonary surfactant in the treatment of neonatal respiratory distress syndrome#br# |
| WANG Dandan LI Yalin WAN Yuan |
| Department of Neonatology, Xuancheng People’s Hospital, Anhui Province, Xuancheng 242000, China |
|
|
|
Abstract Objective To investigate the clinical effect and safety of bilevel positive airway pressure (BiPAP) combined with pulmonary surfactant (Poractant Alfa Injection [Curosurf]) in the treatment of neonatal respiratory distress syndrome (NRDS). Methods A total of 80 children with NRDS in Xuancheng People's Hospital of Anhui Province from August 2017 to December 2020 were selected. According to whether or not Curosurf was applied, they were divided into two groups, control group (40 cases) was treated with BiPAP, and observation group (40 cases) was treated with BiPAP combined with Curosurf. The clinical efficacy of two groups were compared, and the high pressure level (p-high), low pressure level (p-low), fraction of inspiration O2 (FiO2), arterial partial pressure of oxygen (PaO2), arterial partial pressure of carbon dioxide (PaCO2) and Oxygen therapy time, non-invasive ventilation time, clinical symptom relief time, and hospital stay of two groups were compared before treatment and two days after treatment. Results The total effective rate of observation group was higher than that of control group, and the difference was statistically significant (P < 0.05). After two days of treatment, P-high, FiO2 in observation group were lower than those before treatment, p-low in two groups were lower than those before treatment, P-high, P-low and FiO2 in observation group were lower than those in control group, and the differences were statistically significant (P < 0.05). After two days of treatment, PaO2 in two groups were higher than those before treatment, PaCO2 in two groups were lower than those before treatment, PaO2 in observation group was higher than that in control group, PaCO2 was lower than that in control group, and the differences were statistically significant (P < 0.05). The oxygen therapy time, non-invasive ventilation time, clinical symptom relief time and hospital stay in observation group were shorter than those in control group, and the differences were statistically significant (P < 0.05). Conclusion BiPAP combined with Curosurf has a significant effect on the treatment of NRDS, which can reduce mechanical ventilation parameters and promote the recovery of children with high safety.
|
|
|
|
|
|
[1] 王文秀，陈波，章伟，等.血清高迁移率族蛋白B1与新生儿呼吸窘迫综合征的相关性研究[J].中国当代儿科杂志，2017，19（4）：398-401.
[2] 吴晨，邓春.新生儿呼吸窘迫征并发支气管肺发育不良的高危因素[J].重庆医科大学学报，2017，42（8）：1016-1022.
[3] Bae CW，Kim CY，Chung SH，et al. History of Pulmonary Surfactant Replacement Therapy for Neonatal Respiratory Distress Syndrome in Korea [J]. J Korean Med Sci，2019， 34（25）：e175.
[4] 梁振宇，孟琼，游楚明.肺超声评分定量评估新生儿呼吸窘迫综合征严重程度及其临床意义[J].中国超声医学杂志，2019，35（9）：779-782.
[5] 胡婧，程雁.枸橼酸咖啡因联合机械通气治疗新生儿呼吸窘迫综合征的疗效[J].中国现代医学杂志，2019，29（7）：108-112.
[6] 霍梦月，梅花，张钰恒，等.低侵入性肺表面活性物质治疗技术治疗新生儿呼吸 窘迫综合征有效性和安全性的Meta分析[J].中国当代儿科杂志，2020，22（7）：721-727.
[7] 白瑞苗，姜毅，郭金珍，等.《2019年欧洲新生儿呼吸窘迫综合征管理指南》推荐意见介绍[J].中华实用儿科临床杂志，2019，34（16）：1201-1203.
[8] Chowdhury N，Giles BL，Dell SD. Full-Term Neonatal Respiratory Distress and Chronic Lung Disease [J]. Pediatr Ann，2019，48（4）：e175-e181.
[9] 杨玉兰，吴本清，苏锦珍，等.经鼻高频通气治疗新生儿呼吸窘迫综合征效果的系统评价[J].中国当代儿科杂志，2018，20（11）：23-29.
[10] Sweet DG，Carnielli V，Greisen G，et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome-2019 Update [J]. Neonatology，2019， 115（4）：432-450.
[11] Sage M，Nadeau M，Forand-Choinière C，et al. Assessing the impacts of total liquid ventilation on left ventricular diastolic function in a model of neonatal respiratory distress syndrome [J]. PLoS One，2018，13（1）：e0191885.
[12] 钱文亚，谢晓恬.外源性肺表面活性物质治疗新生儿呼吸窘迫综合征研究进展[J].临床儿科杂志，2018，36（6）：476-479.
[13] 刘慧强，刘芳，暴丽莎，等.微创应用肺表面活性物质治疗早产儿呼吸窘迫综合征的多中心临床研究[J].中华儿科杂志，2020，58（5）：374-380.
[14] Ali RA，Obeisat SM，Tarawneh LH. Improving nursing knowledge and care for neonates with respiratory distress in Jordan [J]. Int Nurs Rev，2019，66（3）：338-345.
[15] 卢鹏程.经鼻间歇正压通气治疗新生儿呼吸窘迫综合征的临床研究评——《儿科呼吸系统疾病实例分析》[J].介入放射学杂志，2020，29（11）：1182.
[16] 冯晓霞，宋红，周川，等.微创肺表面活性物质治疗及无创高频辅助通气在极低及超低出生体质量儿呼吸窘迫综合征治疗中的应用[J].中华实用儿科临床杂志，2020，35（18）：1388-1393.
[17] 林玲，彭好.肺泡表面活性物质在新生儿呼吸窘迫综合征中的微创应用[J].中华实用儿科临床杂志，2019，34（23）：1834-1837.
[18] 林蔷，黎巧茹，陈简.不同剂量肺表面活性物质对晚期早产/足月新生儿呼吸窘迫综合征患儿的临床研究[J].中国临床药理学杂志，2020，36（6）：610-612.
[19] McPherson C，Wambach JA. Prevention and Treatment of Respiratory Distress Syndrome in Preterm Neonates [J]. Neonatal Netw，2018，37（3）：169-177.
[20] 高晓燕，高倩，寇同欣，等.注射用牛肺表面活性剂预防新生儿呼吸窘迫综合征的Meta分析[J].中国新药杂志，2018，27（19）：2322-2331.
[21] 胥焕，许平.不同制剂肺表面活性物质对早产儿呼吸窘迫综合征的疗效分析[J].中华危重病急救医学，2021， 33（2）：174-179.
[22] 荣箫，周伟，赵小朋，等.微创肺表面活性物质治疗在新生儿呼吸窘迫综合征中的疗效与安全性[J].中华实用儿科临床杂志，2018，33（14）：1071-1074.
[23] Rahtu M，Frerichs I，Waldmann AD，et al. Early Recognition of Pneumothorax in Neonatal Respiratory Distress Syndrome with Electrical Impedance Tomography[J]. Am J Respir Crit Care Med，2019，200（8）：1060-1061.
[24] Elkabany ZA，El-Farrash RA，Shinkar DM，et al. Oxidative stress markers in neonatal respiratory distress syndrome：advanced oxidation protein products and 8-hydroxy-2-deoxyguanosine in relation to disease severity [J]. Pediatr Res，2020，87（1）：74-80.
[25] 陈志凤，胡琪，丁月琴，等.胎龄28~34周早产儿呼吸窘迫综合征INSURE策略失败的高危因素分析[J].广东医学，2018，39（22）：3344-3347.
[26] 王耀霜，杨曼，韩萍，等.布地奈德混悬液氧驱雾化吸入法防治早产儿支气管肺发育不良的效果[J].临床和实验医学杂志，2019，18（19）：2121-2124.
[27] 温可崇，陈广明，梁振才，等.微创肺表面活性物质及无创持续性气道压力在低体重早产儿呼吸窘迫综合征治疗中的应用[J].中国现代医生，2021，59（21）：54-57.
[28] 陈美娟，郝妮娜，施卡文，等.双水平正压通气在早产儿呼吸窘迫综合征的临床应用[J].中国医药科学，2020， 10（18）：98-100，115. |
|
|
|
